PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.68%
Positive EBIT growth while AVXL is negative. John Neff might see a substantial edge in operational management.
22.68%
Positive operating income growth while AVXL is negative. John Neff might view this as a competitive edge in operations.
22.99%
Positive net income growth while AVXL is negative. John Neff might see a big relative performance advantage.
38.32%
Positive EPS growth while AVXL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
38.32%
Positive diluted EPS growth while AVXL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
24.80%
Share count expansion well above AVXL's 1.51%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
24.80%
Diluted share count expanding well above AVXL's 1.51%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
22.87%
Similar OCF growth to AVXL's 22.08%. Walter Schloss would assume comparable operations or industry factors.
22.60%
FCF growth similar to AVXL's 22.08%. Walter Schloss would attribute it to parallel capital spending and operational models.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13974.70%
Negative 10Y OCF/share CAGR while AVXL stands at 38.48%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
19.53%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
73.45%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
-5088.50%
Negative 10Y net income/share CAGR while AVXL is at 22.87%. Joel Greenblatt sees a major red flag in long-term profit erosion.
66.11%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
78.36%
3Y net income/share CAGR above 1.5x AVXL's 11.39%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
2877.65%
10Y equity/share CAGR above 1.5x AVXL's 345.21%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
75.50%
Below 50% of AVXL's 211.07%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-75.29%
Negative 3Y equity/share growth while AVXL is at 53.75%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.74%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-36.19%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-25.49%
Our R&D shrinks while AVXL invests at 20.44%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-16.18%
We cut SG&A while AVXL invests at 6.56%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.